BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38055053)

  • 1. Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment.
    Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2023 Dec; 32(1):8. PubMed ID: 38055053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.
    Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2023 Aug; 31(8):504. PubMed ID: 37528282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
    Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
    Melosky B; Anderson H; Burkes RL; Chu Q; Hao D; Ho V; Ho C; Lam W; Lee CW; Leighl NB; Murray N; Sun S; Winston R; Laskin JJ
    J Clin Oncol; 2016 Mar; 34(8):810-5. PubMed ID: 26573073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.
    Annunziata MC; De Stefano A; Fabbrocini G; Leo S; Marchetti P; Romano MC; Romano I
    Clin Drug Investig; 2019 Sep; 39(9):825-834. PubMed ID: 31264159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Challenge of Skin Treatment Led by Nurses and Pharmacists for Advanced Colorectal Cancer Patients Treated with Anti-EGFR Antibodies].
    Hirata M; Demachi T; Yanagawa T; Yarimizu A; Nomura K; Kuribayashi M; Kimura K; Beppu N; Song J; Takenaka Y; Nishimura Y; Kimura T; Uchino M; Ikeuchi H; Nagai M; Ikeda M; Kataoka K
    Gan To Kagaku Ryoho; 2022 Apr; 49(4):421-424. PubMed ID: 35444126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance.
    Takahashi H; Asaka J; Tairabune T; Ujiie H; Matsuura Y; Nihei S; Kimura T; Chiba T; Kudo K
    J Clin Pharm Ther; 2021 Oct; 46(5):1404-1411. PubMed ID: 34145608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial.
    Amitay-Laish I; Prag-Naveh H; Ollech A; Davidovici B; Leshem YA; Snast I; Popovtzer A; Purim O; Flex D; David M; Brenner B; Ben-Aharon I; Peled N; Hodak E; Stemmer SM
    Dermatology; 2021; 237(6):988-994. PubMed ID: 33378750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis.
    Petrelli F; Borgonovo K; Cabiddu M; Coinu A; Ghilardi M; Lonati V; Barni S
    Br J Dermatol; 2016 Dec; 175(6):1166-1174. PubMed ID: 27214209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
    Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
    Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
    Goto A; Ozawa Y; Koda K; Akahori D; Koyauchi T; Amano Y; Kakutani T; Sato Y; Hasegawa H; Matsui T; Yokomura K; Suda T
    Respir Investig; 2018 Mar; 56(2):179-183. PubMed ID: 29548657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review.
    Leporini C; Saullo F; Filippelli G; Sorrentino A; Lucia M; Perri G; Gattuta GL; Infusino S; Toscano R; Dima G; Olivito V; Paletta L; Bottoni U; De Sarro G
    J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S78-85. PubMed ID: 24347989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B; Ayanoglu BT; Demirdag HG
    Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
    [No Abstract]   [Full Text] [Related]  

  • 16. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
    Lacouture ME; Mitchell EP; Piperdi B; Pillai MV; Shearer H; Iannotti N; Xu F; Yassine M
    J Clin Oncol; 2010 Mar; 28(8):1351-7. PubMed ID: 20142600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
    Tohyama M; Hamada M; Harada D; Kozuki T; Nogami N; Monden N; Kajiwara T; Nishina T
    J Dermatol; 2020 Feb; 47(2):121-127. PubMed ID: 31803963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
    Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
    Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T; Perez-Soler R
    Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.